Stay updated on Pembrolizumab and SRS for Brain Metastases in Breast Cancer: Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and SRS for Brain Metastases in Breast Cancer: Clinical Trial page.

Latest updates to the Pembrolizumab and SRS for Brain Metastases in Breast Cancer: Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check25 days agoChange DetectedUpdated eligibility criteria now allow concurrent hormonal or anti-HER2 therapy if brain metastases progress; MRI criteria were revised to require at least 2 untreated measurable brain metastases (≥3 mm) within two weeks before treatment, and prior subtotal resection is permitted if residual disease <4 cm.SummaryDifference0.5%

- Check39 days agoChange DetectedSite revision history updated: added v3.5.0 and removed v3.4.3.SummaryDifference0.1%

- Check46 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check75 days agoChange DetectedRevision: v3.4.2 is now displayed on the page. The funding-status notice corresponding to Revision: v3.4.1 has been removed.SummaryDifference0.4%

- Check82 days agoChange DetectedAdded a site-wide notice about a lapse in government funding at the top of the page and updated the revision to v3.4.1. The previous revision tag v3.4.0 was removed.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab and SRS for Brain Metastases in Breast Cancer: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and SRS for Brain Metastases in Breast Cancer: Clinical Trial page.